ImmuPharma pushes ahead with drug research efforts

0 25

This makes it a perfect fit for Lupuzor

Boss Dimitri Dimitriou said of the company’s deal with Avion Pharmaceuticals

What it does

ImmuPharma PLC (LON:IMM) is the developer of Lupuzor, a treatment for the autoimmune disease lupus.

Lupus is what’s called a systemic autoimmune disease that occurs when the body’s immune system attacks its own tissues and organs.

Inflammation caused by lupus can affect many different systems, including joints, skin, kidneys, blood cells, brain, heart and lungs.

While, thankfully, it is rare, Lupus’ symptoms are painful and sometimes fatal.

The condition is poorly treated with only one bespoke drug for the condition – Benlysta, developed by GlaxoSmithKline. AstraZeneca is expected to add a second medication when it brings anifrolumab to the market next year.

In May 2020, a study was published that suggested Lupuzor could help to reduce or prevent the occurrence of the cytokine storm seen in coronavirus patients.

How it is doing

For the six months ended June 30, the specialist drug discovery firm reported a pre-tax loss of £2.8mln, narrowed from a £3.3mln loss a year ago.

Looking ahead, the firm said it is awaiting final FDA guidance on the SPA prior to commencing patient recruitment, adding that it is also progressing other research & development (R&D) programs including its anti-fungal Bio-AMP-B therapy with discussions continuing with potential partners.

Immupahrma is also working on an anti-fungal Bio-AMP-B therapy, which has the potential of progressing quickly through initial bio-equivalence trials and a BioGlucagon product – rescue therapy for low sugar events in diabetes’

Discussions for potential partnering opportunities continue. These initiatives create further opportunities in the medium to long term, it said in September.

Immupharma has also taken a 15.4% stake in cancer drug developer Incanthera.

What the boss says: Tim McCarthy, chairman 

“In response to strong investor interest this year, we are delighted to welcome new and returning institutional and private investors as part of three successful capital raisings. This has created a robust financial position with an anticipated cash runway until the end of 2023.

“As we move our key asset, Lupuzor into a new international optimised Phase III trial and continue to progress our development pipeline, the investment thesis of ImmuPharma continues to strengthen.”

Inflexion points

  • US regulator agrees SPA for Lupuzor
  • Progress on Bio-AMP-B therapy and BioGlucagon product
  • Development runway funded until 2023




Leave A Reply

Your email address will not be published.